ENGLEWOOD, CO / ACCESSWIRE / February 11, 2021 / Aytu BioScience, Inc. (NASDAQ: AYTU), reported financial results for its fiscal second quarter ending December 31, 2020, last week, and disclosed completion of the first clinical study evaluating the company’s Healight™ ultraviolet A light catheter technology. “This is an important milestone, and we look forward to continuing discussions with the FDA…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
